CellSource Co., Ltd.
JPX: 4880.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Masayuki Yamakawa
- Employees
- 151
- Headquarters
- Tokyo, Japan
- IPO year
- 2019
- Market cap
- ¥7.2B
- Website
- https://www.cellsource.co.jp
Loading 4880…
Loading profile data…Frequently asked questions about 4880
What does CellSource Co., Ltd. (4880.T) do?
CellSource Co., Ltd. engages in the regenerative medicine-related and consumer businesses. It also offers Signalift, an anti-aging product. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
Where does 4880.T trade?
CellSource Co., Ltd. (4880.T) trades on the Tokyo Stock Exchange.
What sector is 4880.T in?
CellSource Co., Ltd. (4880.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CellSource Co., Ltd.?
Masayuki Yamakawa is the chief executive officer of CellSource Co., Ltd. (4880.T).
Where is CellSource Co., Ltd. headquartered?
CellSource Co., Ltd. is headquartered in Japan.
Does 4880.T pay a dividend?
Yes — CellSource Co., Ltd. (4880.T) paid a trailing twelve-month dividend of JPY 5.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 4880.T go public?
CellSource Co., Ltd. (4880.T) completed its initial public offering in 2019.